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RESUMO
Avaliação Muito Tardia do Uso de Stents 
Farmacológicos para Tratamento de Pacientes com 
Lesões em Enxertos de Veia Safena: Experiência de 
uma Década do Registro DESIRE
Introdução: A intervenção coronária percutânea (ICP) em 
pontes de safena ainda representa um desafio à Cardiologia 
intervencionista, pelas complicações agudas e pela escassez 
de dados referentes à efetividade tardia dos stents farmacoló-
gicos (SFs). Métodos: Entre maio de 2002 e janeiro de 2013, 
pacientes submetidos à ICP com SF no Hospital do Coração 
foram incluídos no Registro DESIRE. Avaliamos os resultados 
de pacientes submetidos à ICP em pontes de safena (grupo 1), 
que foram comparados aos submetidos a ICP em vasos nativos 
(grupo 2). Resultados: De um total de 4.655 pacientes, 311 
foram incluídos no grupo 1 e 4.344, no grupo 2. O grupo 1 
contou com pacientes mais idosos (68,4 ± 9,7 anos vs. 64 
± 11,2 anos; P < 0,01), com mais pacientes do sexo mas-
culino (87,1% vs. 76,7%; P < 0,01) e com maior incidência 
de comorbidades. Angina instável foi a apresentação clínica 
mais frequente nesse grupo. Pacientes do grupo 1 receberam 
stents de maior calibre (3,18 ± 1,11 mm vs. 2,86 ± 0,43 
mm; P < 0,01) e foram submetidos menos frequentemente a 
pré-dilatação (36,3% vs. 50,7%; P < 0,01) e a pós-dilatação 
(38,3% vs. 58,4%; P < 0,01). Apresentaram mais infarto agudo 
do miocárdio não-fatal na fase hospitalar (11,3% vs. 4,1%; 
ABSTRACT
Background: Percutaneous coronary intervention (PCI) in 
saphenous vein grafts remains a challenge for interventional 
cardiology, due to acute complications and the lack of data 
on the late efficacy of drug-eluting stents (DESs). Methods: 
Between May 2002 and January 2013, patients undergoing PCI 
with DES at Hospital do Coração were included in the DESIRE 
Registry. We evaluated the results of patients undergoing PCI in 
saphenous vein grafts (group 1), who were compared to those 
undergoing PCI in native vessels (group 2.) Results: Of a total 
of 4,655 patients, 311 were included in group 1 and 4,344 in 
group 2. Group 1 included older patients (68.4 ± 9.7 years vs. 
64 ± 11.2 years; P < 0.01), more frequently male (87.1% vs. 
76.7%; P < 0.01) with a higher incidence of comorbidities. 
Unstable angina was the most frequent clinical presentation 
in this group. Group 1 patients received large caliber stents 
(3.18 ± 1.11 mm vs. 2.86 ± 0.43 mm; P < 0.01) and were 
less frequently submitted to pre-dilation (36.3% vs. 50.7%; P 
< 0.01) and post-dilation (38.3% vs. 58.4%; P < 0.01). They 
had a higher incidence of non-fatal acute myocardial infarc-
tion during hospitalization (11.3% vs. 4.1%; P < 0.01) and 
late major adverse cardiovascular events (32.8% vs. 13.9%; 
P < 0.01), at the expense of cardiac death (7.7% vs. 3.2%; 
P = 0.02) and target-lesion revascularization (9% vs. 4.3%; 
P < 0.01). Definitive stent thrombosis was more frequent in 
group 1 (3.5% vs. 1%; P < 0.01). Conclusions: Despite the 
unquestionable benefit of DESs in the late outcomes of PCI 
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in complex patients, the treatment of patients with saphenous 
vein graft lesions remains a challenge, with less favorable acute 
and late results than in patients with native vessel lesions.
 
 
DESCRIPTORS: Angioplasty. Drug-eluting stents. Saphenous 
vein. Coronary artery bypass. Coronary restenosis.
Adjunctive drug therapy
For group 1 patients, often with lesions in degen-
erated venous grafts or significant thrombotic burden, 
the routine procedure at the present institution consists 
of a more intense antithrombotic pre-treatment, inclu-
ding dual antiplatelet therapy with acetylsalicylic acid 
(ASA, loading dose of 500 mg and maintenance dose 
of 100 mg a day), clopidogrel (loading dose of 300-600 
mg and maintenance dose of 75 mg a day), and low 
molecular weight heparin (1 mg/kg every 12 hours), 
whenever possible, for five to seven days before PCI. 
After the procedure, ASA is maintained indefinitely and 
clopidogrel for at least 12 months. The control group 
(group 2) received routine pre-treatment (ASA load-
ing dose of 500 mg and clopidogrel loading dose of 
300-600 mg) for 24 hours before the procedure.
The use of other drugs, such as glycoprotein IIb/IIIa 
inhibitors and adjunct devices, such as distal protection 
filters, and the type of DES to be implanted were at 
the discretion of each surgeon. 
Study definitions
Technical success was considered when a residual 
lesion < 20% was attained without the presence of 
thrombi, changes in coronary flow, or dissections at 
the implanted prosthesis edges.
Deaths were classified as cardiac and non-cardiac. 
Deaths of undetermined causes were considered cardiac. 
Myocardial infarctions were classified based on the 
electrocardiographic changes during evolution, increased 
enzyme concentration (creatine kinase MB fraction 
[CK – MB] > two-fold normal levels) or both findings.
All reoperations resulting from lesion recurrence 
within the stent implanted in the index procedure or 
vascular segment, which included the 5 mm proximal 
and 5 mm distal to the stent, were classified as target 
lesion revascularization (TLR). As this is a real-world 
registry, all restenoses were associated with symptom 
recurrence and/or positive functional tests. Other re-
peated procedures in the same vessel, but outside the 
described segment were classified as revascularization 
of non-target lesion.
P < 0,01) e mais eventos cardiovasculares adversos maiores 
na fase tardia (32,8% vs. 13,9%; P < 0,01), à custa de óbito 
cardíaco (7,7% vs. 3,2%; P = 0,02) e de revascularização da 
lesão-alvo (9% vs. 4,3%; P < 0,01). Trombose definitiva do 
stent foi mais frequente no grupo 1 (3,5% vs. 1%; P < 0,01).
DESCRITORES: Angioplastia. Stents farmacológicos. Veia safena. 
Ponte de artéria coronária. Reestenose coronária.
T he treatment of lesions in saphenous vein grafts persists as a challenge in the current phase of interventional cardiology, given the higher rate 
of acute complications and poor clinical outcome 
in the long term. Although drug-eluting stents (DES) 
have reduced restenosis rates in virtually all clinical 
and angiographic scenarios, improving the outcomes 
of percutaneous coronary intervention (PCI), there are 
still doubts regarding the late efficacy and safety of 
these new devices when used in treatment of lesions 
in saphenous vein bypass grafts. 
This study presents the in-hospital and very late 
clinical results of a consecutive, unselected cohort of 
patients with lesions in saphenous vein grafts treated 
exclusively with DES.
METHODS
Study Population
Since May of 2002, upon approval the first DES 
for clinical use in Brazil, the Drug Eluting Stents In the 
Real World (DESIRE) registry was started at Hospital do 
Coração da Associação do Sanatório Sírio (HCor – São 
Paulo, SP), consecutive and prospectively including all 
patients treated with at least one DES.
The present analysis included patients registered in 
the Hospital’s database until January 2013, and excluded 
patients who received DES and bare-metal stents (BMS) 
at the same procedure. Virtually all clinical scenarios 
are represented in this analysis, except primary rescue 
and PCIs, as the authors considered that the concomitant 
inclusion of venous grafts and myocardial infarction 
with ST-segment elevation segment could represent a 
significant bias in result interpretation, since it is known 
that both scenarios are associated with worse outcomes 
after PCI. Patients whose target lesion was a segment 
with restenosis of a previously implanted stent (whether 
DES or not) were also excluded. 
The remaining patients were then divided into two 
groups for comparison: group  1, patients with lesions 
in saphenous vein grafts, and group 2, patients with 
lesions in native coronary arteries.
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Stent thrombosis was classified according to the 
definition proposed by the Academic Research Con-
sortium: definite (angiographic or anatomopathological 
confirmation), probable (sudden death 30 days after 
PCI or infarction related to the treated artery region, 
even without angiographic confirmation), and possible 
(sudden death > 30 days post-PCI). As for the temporal 
classification, prosthetic thromboses were divided into 
acute and sub-acute (up to 30 days), late (31 to 360 
days), and very late (> 360 days).
During hospitalization, all patients were submitted 
to electrocardiographic and biochemical markers evalu-
ation (CK-MB and troponin), at three different moments: 
before and after the intervention, and, when necessary, 
at hospital discharge.
A dedicated database was developed, which contained 
detailed data on clinical and angiographic characteristics 
and technical information on the intervention of each 
of the registered patients. The hospital evolution data 
and those obtained in the late phase (one month, six 
months, 12 months, and annually thereafter) after the 
index procedure were also recorded.
Statistical analysis
Continuous variables are shown as means and 
standard deviations. Categorical variables are shown as 
numbers and percentages. Student’s t-test was used to 
compare means and the chi-squared test was used to 
compare proportions. P-values < 0.05 were considered 
statistically significant.
RESULTS
From May of 2002 to January of 2013, of a total 
of 4,665 patients from the DESIRE registry that met 
the criteria of this study, 311 had lesions treated in 
saphenous vein grafts (group 1) and 4,344 had lesions 
treated in native vessels (group 2). 
Regarding clinical characteristics (Table 1), patients 
in group 1 were more often males (87.1% vs. 76.7%; 
P < 0.01), older (68.4 ± 9.7 years vs. 64 ± 11.2 years; 
P <  0.01), and had greater incidence of comorbidities, 
especially chronic renal failure (17% vs. 8.2%; P < 0.01). 
The incidence of diabetes mellitus, however, did not 
differ between the groups (34.1% vs. 30.3%; P = 0.16). 
The most common initial clinical presentation in group 
1 was coronary syndrome without ST-segment elevation 
(44.4% vs. 36.9%). The mean age of venous grafts was 
11.3 ± 5.3 years. 
Regarding the angiographic and procedural char-
acteristics (Table 2), patients in group 1 had greater 
reference diameter of the treated vessel (3.03 ± 0.68 
mm vs. 2.72 ± 0.65 mm; P < 0.01), with equal lesion 
TABLE 1  
Baseline clinical characteristics
Group 1
(n = 311 
patients)
Group 2
(n = 4,344 
patients) P
Age, years 68.4 ± 97 64 ± 11.2 < 0.01
Male gender, n (%) 271 (87.1) 3,333 (76.7) < 0.01
Arterial hypertension, n (%) 262 (84.2) 3,308 (76.2) < 0.01
Dyslipidaemia, n (%) 223 (71.7) 2,695 (62) < 0.01
Diabetes mellitus, n (%) 106 (34.1) 1,316 (30.3) 0.16
Smoking, n (%) 75 (24.1) 1,333 (30.7) 0.015
Obesity, n (%) 82 (26.4) 1,168 (26.9) 0.89
Renal failure, n (%) 53 (17) 355 (8.2) < 0.01
Family history of coronary artery disease, n (%) 104 (33.4) 1,575 (36.3) 0.33
Previous acute myocardial infarction, n (%) 106 (34.1) 957 (22) < 0.01
Previous percutaneous coronary intervention, n (%) 83 (26.7) 1,059 (24.4) 0.38
Clinical presentation, n % < 0.01
Stable angina/silent ischaemia 170 (54.7) 2,570 (59.2)
Acute coronary syndrome without ST-segment elevation 138 (44.4) 1,603 (36.9)
Acute coronary syndrome with ST-segment elevation (> 72 hours) 3 (0.9) 171 (3.9)
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extension (17 ± 8.2 mm vs. 17.6 ± 8.7 mm; P = 0.12). 
The presence of thrombus was more frequent in this 
group (9% vs. 2.6 %; P <  0.01). 
Pre-dilation (36.3% vs. 50.7%; P < 0.01) and post-
dilation procedures (38.3% vs. 58.4%; P < 0.01) were 
less frequent in the treatment of lesions in saphenous 
vein grafts. Distal protection filters were used in 4.1% 
of patients in group 1.
Clinical follow-up was attained in 97% of patients 
(median follow-up of 4.7 years). Patients with lesions 
in saphenous vein grafts had more non-fatal acute 
myocardial infarction during hospitalization (11.3% 
vs. 4.1%; P < 0.01), but there were no differences in 
death (0.3% vs. 0.2%; P = 0.60) or emergency target-
lesion revascularization rates (0% vs. 0.02%; P > 0.99). 
At the late phase, these patients presented a higher 
incidence of major adverse cardiac events (32.8% vs. 
13.9%; P  <  0.01), cardiac mortality (7.7% vs. 3.2%; 
P = 0.02), and repeat revascularization of the target-
lesion (9% vs. 4.3%; P < 0.01) (Table 3). The incidence 
of definite thrombosis was also more frequent in this 
group (3.5% vs. 1%; P < 0.01) (Table 4).
DISCUSSION
The main findings of the present study were: 1) 
compared to PCI in native vessels, the percutaneous 
approach of saphenous grafts, even with DES, had a 
more adverse evolution, from the in-hospital phase 
until a later phase; 2) the main adverse event related 
to the percutaneous approach of saphenous grafts was 
the occurrence of periprocedural infarction, probably 
related to the embolization of debris.
Patients with obstructive disease in saphenous 
grafts are usually older, present more comorbidities, 
and greater risk of adverse events when submitted to 
a new coronary artery bypass graft (CABG) surgery.1 
Thus, PCI in saphenous grafts became the preferred 
method of treatment for these patients, accounting 
for 5% to 10% of all PCIs performed in clinical 
practice.2
TABLE 2  
Baseline angiographic and procedural characteristics 
Group 1
(n = 553 lesions)
Group 2
(n = 6,735 lesions) P
Treated vessel, n% NA
Saphenous vein graft to the left anterior descending artery 77 (13.9) –
Saphenous vein graft to the diagonal 106 (19.2) –
Saphenous vein graft to the marginal 205 (37.1) –
Saphenous vein graft to the right coronary 165 (29.8) –
Right coronary artery – 1,908 (28.3)
Left anterior descending artery – 2,933 (43.50
Left circumflex artery – 1,812 (26.9)
Left main coronary artery – 82 (1.3)
Reference diameter 3.03 ± 0.68 2.72 ± 0.65 < 0.01
Lesion length 17 ± 8.2 17.6 ± 8.7 0.12
Calcification, n (%) < 0.01
Mild 456 (82.4) 5,042 (75)
Moderate 93 (17) 1,546 (23)
Severe 4 (0.72) 147 (2.18)
Presence of thrombus, n (%) 50 (9) 173 (2.6) < 0.01
Pre-dilatation, n (%) 201 (36.3) 3,418(50.7) < 0.01
Post-dilatation, n (%) 212 (38.3) 3,936 (58.4) < 0.01
Stent diameter, mm 3.18 ± 1.11 2.86 ± 0.43 < 0.01
Stent length, mm 19.9 ± 6 20.1 ± 6.4 0.48
Distal filter protection, n (%) 23 (4.1) 0 < 0.01
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Although initial observational and retrospective 
studies have reported the superiority of DES over BMS 
in decreasing adverse events (mainly restenosis and 
new revascularisations) in venous grafts interventions,3,4 
data from randomized trials have shown discrepant 
results. The randomized trial Reduction of Restenosis 
In Saphenous vein grafts with Cypher sirolimus-eluting 
stent (RRISC), which included 75 patients, presented 
lower late luminal loss and lower restenosis and new 
revascularizations rates at six months with sirolimus-
eluting stents (SES) when compared with BMS.5 How-
ever, although without statistical power to evaluate 
clinical outcomes, the post-hoc analysis of that study 
with three years of follow-up reported similar rates of 
target-vessel revascularization between SES and BMS, in 
addition to a significantly higher rate of mortality from 
all causes with SES, which raised questions regarding 
the long-term safety of using DES in the treatment of 
degenerated venous grafts.
The findings of that study were not replicated in 
subsequent series, including the largest randomized 
trial specific for this scenario, Is drug–eluting Stenting 
Associated with Improved Results in Coronary Artery 
Bypass Grafts” (ISAR – CABG), which randomized 610 
patients for the treatment of degenerated venous grafts 
with DES or BMS. The occurrence of combined primary 
outcome at 12 months (death, infarction, or target-lesion 
revascularization guided by ischemia) was significantly 
lower in patients treated with DES (15% vs. 22%; P = 
0.03) than in those treated with BMS. There were no 
significant differences between groups regarding the oc-
currence of death, infarction, or stent thrombosis, with 
a difference in primary outcome reflecting a relative risk 
reduction of approximately 50% of new revasculariza-
tion with the use of DES. Angiographic study at six to 
eight months was performed in 72% of patients, which 
demonstrated that the DES had significantly lower rates 
of binary restenosis (15% vs. 29%; P < 0.0001) and graft 
occlusion (6% vs. 12%; P = 0.02).6 Although at a first 
glance the adverse event rates in the DESIRE registry 
appear to be relatively high, it is important to note that 
the literature does not offer very late follow-up (> three 
years) data for patients treated with DES in saphenous 
vein grafts; therefore, it becomes difficult to compare 
the present experience with the international context. 
However, is always important to recall the natural 
history of venous grafts, in which the progression of 
TABLE 3  
Incidence of major adverse cardiac events
Group 1
(n = 311 pacients)
Group 2
(n = 4,344 pacients) P
Hospital phase, n (%)
Cardiac death 1 (0.3) 9 (0.2) 0.60
Non-fatal acute myocardial infarction 35 (11.3) 179 (4.1) < 0.01
Emergency target-lesion revascularisation 0 1 (0.02) > 0.99
Late phase, n (%)
Cardiac death 24 (7.7) 138 (3.2) 0.02
Non-fatal acute myocardial infarction 14 (4.5) 89 (2) 0.08
Target-lesion revascularisation 28 (9) 187 (4.3) 0.08
Cumulative major adverse cardiac event, (%) 102 (32.8) 603 (13.9) < 0.01
TABLE 4  
Incidence of stent thrombosis
Group 1
(n = 311 pacients)
Group 2
(n = 4,344 pacients) P
Definite, n (%) 11 (3.5) 44 (1) < 0.01
Probable, n (%) 0 2 (0.05) > 0.99
Possible, n (%) 4 (1.3) 41 (0.94) 0.54
Total, n (%) 15 (4.8) 87 (2) < 0.01
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atherosclerotic disease occurs more rapidly. At the end 
of five years, approximately 20% to 35% of the grafts 
are occluded, while at the end of a decade, 50% are 
occluded and approximately half of patent grafts are 
already degenerated.7
In such a difficult context, 32.7% MACE in up to 
ten years of follow-up (median 4.7 years) appears to 
be favourable, although the authors believe that this is 
one of fields in which interventional cardiology needs 
to progress, as the current results are still quite below 
those obtained with native vessels.
CONCLUSIONS
Despite the unquestionable benefits of DES on 
the late outcomes of PCI in complex patients, the 
percutaneous treatment of patients with saphenous 
vein graft lesions remains a challenge to interventional 
cardiology, with less favorable acute and late outcomes 
than those in native vessels. However, is worth men-
tioning that, to date, these tools still remain the best 
option for the percutaneous treatment of venous graft 
lesions.
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